Categories: ITPlatformTechnologyBioTechDeliveryDevelopment
Rampart Bioscience is developing a novel non-viral gene therapy platform based on a proprietary HALO DNA technology that has been designed to deliver genetic medicines effectively and durably, and to overcome key limitations and safety concerns of viral and early non-viral gene therapy approaches. Rampart is validating its platform with a novel treatment for hypophosphatasia (HPP), a rare, often fatal genetic disease that prevents bone mineralization. The company has multiple additional programs in development as it aims to develop novel treatment options for patients with genetic diseases.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.10.2023 | Series A | $85M | Forbion |
Mentions in press and media 4
Reviews 0
